Molecular Targets in Protein Misfolding and Neurodegenerative Disease (eBook)

Pierfausto Seneci (Autor)

eBook Download: PDF | EPUB

2014 | 1. Auflage
314 Seiten
Elsevier Science (Verlag)
978-0-12-800499-9 (ISBN)

Infos

Aimed at 'drug discoverers' - i.e. any scientist who is interested in neurodegenerative diseases in general, and in finding disease-modifying treatments in particular - the first edition of Molecular Targets in Protein Misfolding and Neurodegenerative Disease will contain both a detailed, discipline-specific coverage (paragraphs on medicinal chemistry, on clinical and preclinical characterization of compounds in development, on target identification and validation, on genetic factors influencing a pathology, etc.) and a drug discovery-oriented, overall evaluation of each target (validation, druggability, existing leads, etc.). Together these will satisfy the needs of various audiences, including in vitro biologists, pharmacologists, medicinal chemists, etc. - Written to provide a comprehensive coverage of disease-modifying mechanisms and compounds against neurodegenerative diseases - Provides a 'drug discovery application oriented perspective, evaluating targets and candidates for their overall therapeutic potential - Provides discipline-specific chapters (medicinal chemistry, target validation, preclinical and clinical development - Provides an overview on a number of molecular mechanisms (e.g. phosphorylation, chaperon refolding, ubiquitination, autophagy, microtubule transportation, protease cleavage, etc.) with relevance for any disease area - Contains a more thorough description of the therapeutic relevance of -10 specific molecular targets

Dr. Pierfausto Seneci is Associate Professor in the Department of Organic and Industrial Chemistry at the University of Milan. He is currently affiliated with the University of Milan Centre for Interdisciplinary Biomolecular Studies and Industrial Applications (CISI) Centre of Excellence, and is responsible for the Combinatorial Chemistry/High Throughput MedChem Laboratory. He has over 20 years of medicinal chemistry experience working in industry, and held business development positions with GSK, Sanofi, and start-up pharmaceutical companies including Sirenade and NiKem working in drug discovery, neurodegeneration, oncology, and antibacterials. He is author of approximately 80 papers on the topic and several book chapters, including the book 'Solid-Phase Synthesis and Combinatorial Technologies” with Wiley-Interscience in 2000.

---

Aimed at "e;drug discoverers"e; - i.e. any scientist who is interested in neurodegenerative diseases in general, and in finding disease-modifying treatments in particular - the first edition of Molecular Targets in Protein Misfolding and Neurodegenerative Disease will contain both a detailed, discipline-specific coverage (paragraphs on medicinal chemistry, on clinical and preclinical characterization of compounds in development, on target identification and validation, on genetic factors influencing a pathology, etc.) and a drug discovery-oriented, overall evaluation of each target (validation, druggability, existing leads, etc.). Together these will satisfy the needs of various audiences, including in vitro biologists, pharmacologists, medicinal chemists, etc. - Written to provide a comprehensive coverage of disease-modifying mechanisms and compounds against neurodegenerative diseases- Provides a "e;drug discovery application oriented perspective, evaluating targets and candidates for their overall therapeutic potential- Provides discipline-specific chapters (medicinal chemistry, target validation, preclinical and clinical development- Provides an overview on a number of molecular mechanisms (e.g. phosphorylation, chaperon refolding, ubiquitination, autophagy, microtubule transportation, protease cleavage, etc.) with relevance for any disease area- Contains a more thorough description of the therapeutic relevance of ~10 specific molecular targets

Textauszug

Abbreviations

4EBP1    4E-binding protein 1

AA    amino acid

AAA+    ATPases associated with various cellular activities

Aβ    amyloid β

ABIN    A20 binding inhibitor of NF-kappaB

ACD    α-crystallin domain

AChE    acetylcholinesterase

AD    Alzheimer’s disease

ADI    Alzheimer’s disease international

Adrm1    adhesion regulating molecule 1

AFM    atomic force microscopy

Ag    aggregate

AgD    argyrophilic disease

AgR    aggrephagy receptor

AgS    aggrephagy scaffold

Aha1    activator of Hsp90 ATPase

AIM    Atg8-interacting motif

Akt    protein kinase B

ALFY    autophagy linked FYVE protein

ALR    autophagic lysosomal reformation

ALS    amyotrophic lateral sclerosis

AMBRA1    autophagy/beclin 1 regulator 1

AmF    amyloid fiber

AMPA    α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

AMPK    AMP-activated protein kinase

AN    aggregation nuclei

AMSH-LP    associated molecule with the SH3 domain of STAM-like protein

AP    autophagosomes

APD    atypical parkinsonism disorder

APOE    apolipoprotein E

APP    amyloid precursor protein

ARA54    AR-associated protein 54

ARCA    autosomal recessive cerebellar ataxia

ARIH    ariadne homolog

Atg    autophagy-related

AV    autophagic vacuoles

BACE1    β-APP cleaving enzyme 1

BAG    Bcl-2-associated athanogene

BARD1    BRCA1–associated RING domain protein 1

Barkor    beclin 1-associated autophagy-related key regulator

BDNF    brain-derived neurotrophic factor

BEACH    PH-Beige and Chediak-Higashi

BH    Bcl-2-homology

BIF-1    BAX-interacting factor-1

Bnip-3    Bcl-2/E1B-19 kDa interacting protein 3

BRCA1    breast cancer type 1

BRMS1    breast cancer metastasis suppressor 1

CA1    cornus ammonis 1

Car    cargo

CASA    chaperone-assisted selective autophagy

Cath A    cathepsin A

CBD    corticobasal degeneration

CD4    cluster of differentiation 4

cdc37    cell division cycle 37 homolog

Cdk    cyclin-dependent kinase

CFTR    cystic fibrosis transmembrane regulator

Ch    cholesterol

CHIP    C-terminus of Hsc70 interacting protein

CHMPB2    charged multivesicular body protein B2

cIAP    cellular Inhibitor of Apoptosis Protein

CK2    casein kinase 2

Clp    caseinolytic protease

CMA    chaperone-mediated autophagy

CMT    Charcot–Marie–Tooth disease

CNS    central nervous system

CP    core particle

CRL    cullin RING ligases

CTE    chronic traumatic encephalopathy

Cvt    cytosol-to-vacuole transport

CYLD    cylindromatosis

Cyp40/Cpr6    cyclophilin 40/cytoplasmic ribosomal protein-6

Cyt    cytosolic

D    dimer

DA    disordered aggregate

DAP1    death-associated protein 1

DAPK    death-associated protein kinase

dAV    degradative autophagic vacuoles

DBM    dynein binding motor

Ddi1    DNA damage-inducible 1

DHMN    distal hereditary motor neuropathy

DLB    dementia with Lewy bodies

DLS    dynamic light scattering

DM1    type I myotonic dystrophy

DNTC    diffuse neurofibrillary tangles with calcification

DRAM    damage-regulated autophagy modulator

DS    Down syndrome

Dsk2    dominant suppressor of kar2

DUB    de-ubiquitinating enzyme

DYN    dynein motors

E1    UBQ-activating enzyme

E2    UBQ-conjugating enzyme

E3    UBQ ligase

E6AP    E6-associated protein

EC    entorhinal cortex

ECD    evolutionary conserved domain

eIF4E    eukaryotic translation initiation factor 4 epsilon

EM    electron microscopy

ER    endoplasmic reticulum

ERAD    endoplasmic reticulum-associated degradation

ERGIC    ER-Golgi intermediate compartment

ERK    extracellular-regulated signal kinase

ES    endosomes

ESCRT    endosomal sorting complex required for transport machinery

ESI    electron spray ionization

FAT    fast axonal transport

FATC    FRAP, ATM, TRRAP C-terminal

FBD    familial British dementia

FDD    familial Danish dementia

FIP200    focal adhesion kinase family-interacting protein

FKBP    FK-binding protein

FL    full length

FRB    FKBP–rapamycin binding

FTDP-17    frontotemporal dementia and parkinsonism linked to chromosome 17

FTLD    frontotemporal lobar degeneration

FUS    fused in sarcoma

FYCO    FYVE and coiled-coil domain containing 1

FYVE    Fab1-YotB-Vac1p-EEA1

G2E3    G2/M-phase-specific E3 UBQ ligase

G3BP1    Ras-GTPase-activating protein SH3 domain-binding protein 1

GABA    γ-aminobutyric acid

GABARAP    GABA receptor-associated proteins

Gad    gracile axonal dystrophy

Gd-PDG    Guadeloupean-parkinsonism dementia complex

GGT    globular glial tauopathies

GOF    gain-of-function

GR    glucocorticoid receptor

GSK-3    glycogen synthase kinase 3

GSS    Gerstmann–Sträussler–Scheinker disease

H    heparin

HACEI1    HECT domain and ankyrin repeat-containing E3 ubiquitin-protein ligase...

Produkt-Details

• Erscheint lt. Verlag: 7.10.2014
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Themenwelt: Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie
• Themenwelt: Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie
• Themenwelt: Naturwissenschaften ► Biologie ► Humanbiologie
• Themenwelt: Naturwissenschaften ► Biologie ► Zoologie
• ISBN-10: 0-12-800499-1 / 0128004991
• ISBN-13: 978-0-12-800499-9 / 9780128004999